实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
12期
1577-1579
,共3页
培美曲塞%吉西他滨%卡铂%晚期非小细胞肺癌
培美麯塞%吉西他濱%卡鉑%晚期非小細胞肺癌
배미곡새%길서타빈%잡박%만기비소세포폐암
Pemetrexed%Gemcitabine%Carboplatin%Advanced non-small cell lung cancer
目的:比较培美曲塞联合卡铂与吉西他滨联合卡铂治疗老年晚期非小细胞肺癌( NSCLC )的疗效及不良反应。方法60例经病理组织学或(和)细胞学检查确诊的ⅢB或Ⅳ期非小细胞肺癌患者,其中培美曲塞组(PC)28例,吉西他滨组(GC)32例,分别给予培美曲塞联合卡铂和吉西他滨联合卡铂方案进行4个周期的治疗。评估近期疗效和不良反应。结果 PC组和GC组的部分缓解率分别为46.4%和43.7%。疾病控制率分别为85.7%和81.2%。 PC组OS=7.3个月;GC组OS=7.0个月,P=0.63。 PC组与GC组3~4级白细胞减少症分别为43.8%和24.9%(P=0.001),中性粒细胞减少症分别为50.0%和42.8%(P=0.024),血小板减少症分别为53.0%和25.0%(P=0.001)。结论培美曲塞联合卡铂和吉西他滨联合卡铂治疗晚期非小细胞肺癌疗效相近,培美曲塞组不良反应少,安全性更好。
目的:比較培美麯塞聯閤卡鉑與吉西他濱聯閤卡鉑治療老年晚期非小細胞肺癌( NSCLC )的療效及不良反應。方法60例經病理組織學或(和)細胞學檢查確診的ⅢB或Ⅳ期非小細胞肺癌患者,其中培美麯塞組(PC)28例,吉西他濱組(GC)32例,分彆給予培美麯塞聯閤卡鉑和吉西他濱聯閤卡鉑方案進行4箇週期的治療。評估近期療效和不良反應。結果 PC組和GC組的部分緩解率分彆為46.4%和43.7%。疾病控製率分彆為85.7%和81.2%。 PC組OS=7.3箇月;GC組OS=7.0箇月,P=0.63。 PC組與GC組3~4級白細胞減少癥分彆為43.8%和24.9%(P=0.001),中性粒細胞減少癥分彆為50.0%和42.8%(P=0.024),血小闆減少癥分彆為53.0%和25.0%(P=0.001)。結論培美麯塞聯閤卡鉑和吉西他濱聯閤卡鉑治療晚期非小細胞肺癌療效相近,培美麯塞組不良反應少,安全性更好。
목적:비교배미곡새연합잡박여길서타빈연합잡박치료노년만기비소세포폐암( NSCLC )적료효급불량반응。방법60례경병리조직학혹(화)세포학검사학진적ⅢB혹Ⅳ기비소세포폐암환자,기중배미곡새조(PC)28례,길서타빈조(GC)32례,분별급여배미곡새연합잡박화길서타빈연합잡박방안진행4개주기적치료。평고근기료효화불량반응。결과 PC조화GC조적부분완해솔분별위46.4%화43.7%。질병공제솔분별위85.7%화81.2%。 PC조OS=7.3개월;GC조OS=7.0개월,P=0.63。 PC조여GC조3~4급백세포감소증분별위43.8%화24.9%(P=0.001),중성립세포감소증분별위50.0%화42.8%(P=0.024),혈소판감소증분별위53.0%화25.0%(P=0.001)。결론배미곡새연합잡박화길서타빈연합잡박치료만기비소세포폐암료효상근,배미곡새조불량반응소,안전성경호。
Objective To compare the efficacy and toxicities of pemetrexed plus carboplatin and gemcitabine plus carbo -platin for elderly patients with advanced non-small cell lung cancer ( NSCLC) .Methods 60 patients with stage ⅢB orⅣnon-small cell cancer were divided into pemetrexed group ( PC) 28 cases and gemcitabine group ( GC) 32 patients.Each group was given pemetrexed plus carboplatin and gemcitabine plus carboplatin for 4 cycles.The short-term efficacy and toxicities of the 2 groups were analyzed.Results Partial remission rates of the PC group and GC group were 46.4%and 43.7%,respectively.The disease control rates of the PC group and GC group were 85.7%and 81.2%,respectively.PC group OS=7.3 months;GC group OS=7.0 months,P=0.63.Stage 3~4 leukopenia of the GC group and the PC group were 43.8% and 24.9% (P=0.001), neutropenia syndrome of the GC group and the PC group were 50.0%and 42.8%(P=0.024),and platelet thrombocytopenia of the GC group and the PC group were 53.0%and 25.0% (P=0.001).Conclusion Pemetrexed plus carboplatin and gemcit-abine plus carboplatin for advanced non-small cell lung cancer has similar efficacy .Pemetrexed plus carboplatin has fewer adverse reactions and better security .